Table 2.
The impact of damage accrual and clinical events related to APS on OPN levels
| Variable | B | p-value |
| SDI / SDI domain | ||
| Global SLICC/ACR DI | 6.5 | <0.0001 |
| Renal | 18.8 | <0.0001 |
| Cardiovascular | 12.3 | <0.0001 |
| Malignancy | 18.1 | 0.012 |
| Clinical APS related events | ||
| Valvular surgery | 38.8 | <0.0001 |
| Valvular heart disease | 26.1 | <0.0001 |
| Myocardial infarction | 17.4 | 0.019 |
| Ischaemic stroke | 14.1 | 0.026 |
| Arterial embolism | 12.6 | 0.031 |
| Any arterial event | 11.3 | 0.044 |
| Pulmonary embolism | 16.9 | 0.053 |
All univariate general linear models are adjusted for sex, age, corticosteroids and disease duration.
APS, antiphospholipid syndrome; OPN, osteopontin; SDI, Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index; SLICC/ACR DI, Systemic Lupus International Collaborating Clinics/American College of Rheumatology Disease Index.